FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Исследования/Highlighting the role of incretin hormones in type 2 diabetes and exploring the therapeutic advancements through GLP-1 and GIP agonists.
Назад в Научную Библиотеку
glucose-dependent insulinotropic polypeptide (GIP)glucagon-like peptide-1 (GLP-1)

Highlighting the role of incretin hormones in type 2 diabetes and exploring the therapeutic advancements through GLP-1 and GIP agonists.

May 17, 2026
Share

Исходная статья

Incretin hormones and type 2 diabetes.

Nauck Michael A et al.Diabetologia2023
Развивающиеся Исследования

Основано на развивающихся исследованиях. Эти выводы обещающи, но требуют дальнейшей проверки.

О данном анализе

Эта статья разбивает выводы из исходной статьи выше на доступный язык для сообщества исследований Peptide. Наша цель — подчеркнуть то, что наиболее важно — практические последствия, надежность доказательств и то, что это означает для текущих исследований.

Harnessing Incretin Hormones: A New Frontier in Type 2 Diabetes Treatment

Published: May 17, 2026 | Source: Diabetologia (2023) | Category: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1)

Overview

A new review in Diabetologia highlights the critical role of incretin hormones, specifically GIP and GLP-1, in managing type 2 diabetes. The study underscores how these hormones can be harnessed to improve glycemic control, cardiorenal outcomes, and body weight management, offering fresh hope for therapeutic advancements.

Study Background

Incretin hormones are naturally occurring peptides that enhance insulin secretion when blood glucose levels rise after eating. Prior research has shown that in type 2 diabetes, the body's ability to use these hormones effectively is diminished, leading to poor glycemic control and other complications. This review synthesizes existing knowledge on how GIP and GLP-1 function and their therapeutic potential through selective agonists or co-agonists.

What the Research Found

The review found that in type 2 diabetes, the body's response to incretin hormones is compromised. Specifically:

  • GIP: Its ability to stimulate insulin secretion is reduced due to impaired beta cell function or signaling pathway defects.
  • GLP-1: Despite a diminished overall incretin effect, GLP-1 retains its potency in stimulating insulin and suppressing glucagon secretion.

The authors also noted that exogenous GLP-1 can significantly improve fasting and postprandial glucose levels. Additionally, the development of newer drugs like tirzepatide, which acts on both GIP and GLP-1 receptors, shows promise for better glycemic control and additional health benefits such as weight loss.

What This Means for Peptide Users

For individuals using peptides to manage type 2 diabetes, this research suggests that incretin-based therapies could offer enhanced efficacy. The use of selective agonists or co-agonists targeting both GIP and GLP-1 receptors may provide a more comprehensive approach to managing blood sugar levels, cardiorenal health, and weight management.

Limitations and Caveats

As a review paper, this study does not present new primary data but rather synthesizes existing literature. The conclusions are based on the quality of previous studies which can vary widely in design and methodology. Additionally, while promising, the long-term efficacy and safety profiles of newer incretin-based therapies like tirzepatide require further investigation.

How This Compares to Previous Research

This review aligns with earlier research highlighting the importance of GIP and GLP-1 in diabetes management but provides a more nuanced understanding of their roles. It also emphasizes recent advancements in therapeutic options, such as dual-receptor co-agonists, which have not been extensively covered before.

Our Analysis

PeptideVault views this review positively for its comprehensive synthesis of existing literature on incretin hormones and type 2 diabetes. The paper effectively outlines the current understanding of GIP and GLP-1's roles in disease pathophysiology and therapeutic potential. However, it is important to acknowledge that further clinical trials are necessary to validate these findings and establish long-term safety profiles.

Key Takeaways

  • Incretin Hormones: Play a crucial role in regulating blood sugar levels.
  • Therapeutic Potential: GLP-1 agonists and dual-receptor co-agonists show promise for better glycemic control.
  • Future Directions: More research is needed to understand long-term efficacy and safety of incretin-based therapies.

Original Source

Citation: Nauck Michael A, Müller Timo D (2023). Incretin hormones and type 2 diabetes. Diabetologia. DOI: 10.1007/s00125-023-05956-x

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Примечание Редактора

Этот анализ был подготовлен командой исследований Peptide Contacts. Мы призываем читателей проверить полный исходный источник полная методология и данные. Исходное издание доступно на PubMed.

Comments

Sign in to join the discussion

Этот анализ сгенерирован на основе рецензированных исследований для образовательных целей только. Это не является медицинским советом. Всегда консультируйтесь с квалифицированным медицинским специалистом перед использованием каких-либо терапий на основе Peptide.